{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:15:51Z","timestamp":1777590951096,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"am","delay-in-days":313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000774","name":"DTRA","doi-asserted-by":"publisher","award":["HDTRA1-13-1-0006"],"award-info":[{"award-number":["HDTRA1-13-1-0006"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.antiviral.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T14:05:37Z","timestamp":1530799537000},"page":"57-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses"],"prefix":"10.1016","volume":"157","author":[{"given":"Lindsay","family":"Lundberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwini","family":"Brahms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idris","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2942-5937","authenticated-orcid":false,"given":"Shih-Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8746-7954","authenticated-orcid":false,"given":"Bibha","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarthi","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kylene","family":"Kehn-Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.antiviral.2018.07.005_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036327","article-title":"p53 activation following Rift Valley fever virus infection contributes to cell death and viral production","volume":"7","author":"Austin","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.005_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.tplants.2017.01.008","article-title":"eIF4E resistance: natural variation should guide gene editing","volume":"22","author":"Bastet","year":"2017","journal-title":"Trends Plant Sci."},{"key":"10.1016\/j.antiviral.2018.07.005_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fmicb.2015.00676","article-title":"Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection","volume":"6","author":"Benedict","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2018.07.005_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fmicb.2015.00676","article-title":"Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection","volume":"6","author":"Benedict","year":"2015","journal-title":"Front. Microbiol."},{"issue":"21","key":"10.1016\/j.antiviral.2018.07.005_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00968-17","article-title":"Sorafenib impedes Rift Valley fever virus egress by inhibiting valosin-containing protein function in the cellular secretory pathway","volume":"91","author":"Brahms","year":"2017","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.005_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.febslet.2005.12.071","article-title":"Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication","volume":"580","author":"B\u00fcrckst\u00fcmmer","year":"2006","journal-title":"FEBS (Fed. Eur. Biochem. Soc.) Lett."},{"key":"10.1016\/j.antiviral.2018.07.005_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02068-17","article-title":"Protein phosphatase 1 alpha interacts with venezuelan equine encephalitis virus capsid protein and regulates viral replication through modulation of capsid phosphorylation","author":"Carey","year":"2018","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.antiviral.2018.07.005_bib8","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.ejmech.2011.04.007","article-title":"Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf","volume":"46","author":"Chen","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.antiviral.2018.07.005_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004213","article-title":"Discovery of a novel compound with anti-venezuelan equine encephalitis virus activity that targets the nonstructural protein 2","volume":"10","author":"Chung","year":"2014","journal-title":"PLoS Pathog."},{"issue":"Suppl. C","key":"10.1016\/j.antiviral.2018.07.005_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2015.03.012","article-title":"The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro","volume":"118","author":"Descamps","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.005_bib11","unstructured":"FDA. Highlights of Prescribing Information 2013 [11\/06\/2017]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=021923."},{"key":"10.1016\/j.antiviral.2018.07.005_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coviro.2017.07.024","article-title":"Generation of novel resistance genes using mutation and targeted gene editing","volume":"26","author":"Gal-On","year":"2017","journal-title":"Curr. Opin. Virol."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.005_bib13","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1128\/JVI.02073-06","article-title":"The Old World and New World alphaviruses use different virus-specific proteins for induction of transcriptional shutoff","volume":"81","author":"Garmashova","year":"2007","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.antiviral.2018.07.005_bib14","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1128\/JVI.06449-11","article-title":"Attenuation of Chikungunya virus vaccine strain 181\/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein","volume":"86","author":"Gorchakov","year":"2012","journal-title":"J. Virol."},{"issue":"4S","key":"10.1016\/j.antiviral.2018.07.005_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7205\/MILMED.170.4S.92","article-title":"History of U.S. Military contributions to the study of viral encephalitis","volume":"170","author":"Hoke","year":"2005","journal-title":"Mil. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.005_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejcb.2012.09.001","article-title":"The kinase inhibitor Sorafenib impairs the antiviral effect of interferon \u03b1 on hepatitis C virus replication","volume":"92","author":"Himmelsbach","year":"2013","journal-title":"Eur. J. Cell Biol."},{"issue":"12","key":"10.1016\/j.antiviral.2018.07.005_bib17","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1136\/gut.2009.182212","article-title":"New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication","volume":"58","author":"Himmelsbach","year":"2009","journal-title":"Gut"},{"issue":"21","key":"10.1016\/j.antiviral.2018.07.005_bib18","doi-asserted-by":"crossref","first-page":"12213","DOI":"10.1128\/JVI.01650-14","article-title":"Sapovirus translation requires an interaction between VPg and the cap binding protein eIF4E","volume":"88","author":"Hosmillo","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.07.005_bib19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/leu.2011.2","article-title":"Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1","volume":"25","author":"Huber","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.005_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005091","article-title":"Inhibition of mTORC1 enhances the translation of chikungunya proteins via the activation of the MnK\/eIF4E pathway","volume":"11","author":"Joubert","year":"2015","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.005_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.antiviral.2008.07.002","article-title":"Treatment of Venezuelan equine encephalitis virus infection with (\u2212)-carbodine","volume":"80","author":"Julander","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.005_bib22","series-title":"Mosquitoes [Licensed under a Creative Commons Attribution License]","author":"Jupp","year":"2013"},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.005_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034761","article-title":"Modulation of GSK-3\u03b2 activity in venezuelan equine encephalitis virus infection","volume":"7","author":"Kehn-Hall","year":"2012","journal-title":"PLoS One"},{"issue":"28","key":"10.1016\/j.antiviral.2018.07.005_bib24","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.3748\/wjg.15.3472","article-title":"Targeting host factors: a novel rationale for the management of hepatitis C virus","volume":"15","author":"Khattab","year":"2009","journal-title":"World J. Gastroenterol."},{"issue":"16","key":"10.1016\/j.antiviral.2018.07.005_bib25","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1128\/JVI.00644-11","article-title":"Conservation of a packaging signal and the viral genome RNA packaging mechanism in alphavirus evolution","volume":"85","author":"Kim","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.07.005_bib26","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s10637-010-9585-1","article-title":"The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates","volume":"30","author":"Kim","year":"2012","journal-title":"Invest. N. Drugs"},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.005_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0042-6822(89)90347-4","article-title":"The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83","volume":"170","author":"Kinney","year":"1989","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.005_bib28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1128\/jvi.67.3.1269-1277.1993","article-title":"Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein","volume":"67","author":"Kinney","year":"1993","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.antiviral.2018.07.005_bib29","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Canc. Res."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.005_bib30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.antiviral.2013.10.004","article-title":"Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication","volume":"100","author":"Lundberg","year":"2013","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.antiviral.2018.07.005_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005122","article-title":"Selective inhibitor of nuclear export (SINE) compounds alter New World alphavirus capsid localization and reduce viral replication in mammalian cells","volume":"10","author":"Lundberg","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"Suppl. C","key":"10.1016\/j.antiviral.2018.07.005_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2014.10.002","article-title":"Small molecule inhibitors of Ago2 decrease Venezuelan equine encephalitis virus replication","volume":"112","author":"Madsen","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.005_bib33","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1046\/j.0014-2956.2001.02478.x","article-title":"Phosphorylation of eukaryotic initiation factor 4E (eIF4E) at Ser209 is not required for protein synthesis in vitro and in vivo","volume":"268","author":"McKendrick","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"17","key":"10.1016\/j.antiviral.2018.07.005_bib34","doi-asserted-by":"crossref","first-page":"9278","DOI":"10.1128\/JVI.77.17.9278-9286.2003","article-title":"Recombinant sindbis\/venezuelan equine encephalitis virus is highly attenuated and immunogenic","volume":"77","author":"Paessler","year":"2003","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.005_bib35","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1158\/1535-7163.MCT-10-0274","article-title":"Sorafenib activates CD95 and promotes autophagy and cell death via src family kinases in gastrointestinal tumor cells","volume":"9","author":"Park","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"issue":"50","key":"10.1016\/j.antiviral.2018.07.005_bib36","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1016\/j.vaccine.2011.09.130","article-title":"Rapid, non-invasive imaging of alphaviral brain infection: reducing animal numbers and morbidity to identify efficacy of potential vaccines and antivirals","volume":"29","author":"Patterson","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.005_bib37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.antiviral.2018.07.005_bib38","doi-asserted-by":"crossref","first-page":"10118","DOI":"10.1128\/JVI.75.21.10118-10131.2001","article-title":"Evolutionary relationships and systematics of the alphaviruses","volume":"75","author":"Powers","year":"2001","journal-title":"J. Virol."},{"issue":"42","key":"10.1016\/j.antiviral.2018.07.005_bib39","doi-asserted-by":"crossref","first-page":"35217","DOI":"10.1074\/jbc.M506551200","article-title":"Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation","volume":"280","author":"Rahmani","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.antiviral.2018.07.005_bib40","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1128\/MCB.01080-06","article-title":"The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress","volume":"27","author":"Rahmani","year":"2007","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.005_bib41","first-page":"413","article-title":"Alphavirus antiviral drug development: scientific gap analysis and prospective research areas","volume":"7","author":"Reichert","year":"2009","journal-title":"Biosecur. Bioterrorism Biodefense Strategy, Pract. Sci."},{"issue":"31","key":"10.1016\/j.antiviral.2018.07.005_bib42","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1200\/JCO.2017.73.8245","article-title":"Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study","volume":"35","author":"Reiss","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.antiviral.2018.07.005_bib43","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.antiviral.2018.07.005_bib44","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1074\/jbc.M114.602649","article-title":"Murine norovirus 1 (MNV1) replication induces translational control of the host by regulating eIF4E activity during infection","volume":"290","author":"Royall","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.antiviral.2018.07.005_bib45","doi-asserted-by":"crossref","first-page":"8608","DOI":"10.1021\/jm501203v","article-title":"Development of (E)-2-((1,4-Dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus","volume":"57","author":"Schroeder","year":"2014","journal-title":"J. Med. Chem."},{"issue":"29","key":"10.1016\/j.antiviral.2018.07.005_bib46","doi-asserted-by":"crossref","first-page":"re8","DOI":"10.1126\/scisignal.129re8","article-title":"Host-directed drug targeting of factors hijacked by pathogens","volume":"1","author":"Schwegmann","year":"2008","journal-title":"Sci. Signal."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2018.07.005_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(02)00203-6","article-title":"Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control","volume":"57","author":"Sidwell","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.07.005_bib48","series-title":"Non-flavivirus Encephalitis","author":"Slobodan Paessler","year":"2011"},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.005_bib49","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/0300985810372508","article-title":"REVIEW paper pathology of animal models of alphavirus encephalitis","volume":"47","author":"Steele","year":"2010","journal-title":"Vet. Pathol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.07.005_bib50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol. Rev."},{"issue":"5","key":"10.1016\/j.antiviral.2018.07.005_bib51","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.antiviral.2018.07.005_bib52","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1073\/pnas.1507499112","article-title":"Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition","volume":"112","author":"Su","year":"2015","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"7","key":"10.1016\/j.antiviral.2018.07.005_bib53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrrheum.2012.64","article-title":"Arthritogenic alphaviruses\u2014an overview","volume":"8","author":"Suhrbier","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.antiviral.2018.07.005_bib54","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1128\/JVI.02990-13","article-title":"Stable, high-level expression of reporter proteins from improved alphavirus expression vectors to track replication and dissemination during encephalitic and arthritogenic disease","volume":"88","author":"Sun","year":"2014","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2018.07.005_bib55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2015.05.049","article-title":"Differential requirements for eIF4E dose in normal development and cancer","volume":"162","author":"Truitt","year":"2015","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.antiviral.2018.07.005_bib56","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Canc. Res."},{"issue":"19","key":"10.1016\/j.antiviral.2018.07.005_bib57","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Canc. Res."},{"key":"10.1016\/j.antiviral.2018.07.005_bib58","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.antiviral.2018.07.005_bib59","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Canc. Therapeut."},{"issue":"11","key":"10.1016\/j.antiviral.2018.07.005_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143467","article-title":"Viral genome-linked protein (VPg) is essential for translation initiation of rabbit hemorrhagic disease virus (RHDV)","volume":"10","author":"Zhu","year":"2015","journal-title":"PLoS One"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218300640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218300640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:02Z","timestamp":1759062422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218300640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":60,"alternative-id":["S0166354218300640"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}